| Name | Genflow Biosciences |
|---|---|
| Epic | GENF |
| Isin | GB00BP2C3V08 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 2.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £9.87 | Debt ratio | n/a |
| Shares in issue | 493.55 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 393.8 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.47 | 52-week high / low | 0.62p / 2.25p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Genflow Biosciences |
|---|---|
| Address | Suite 1, 15 Ingestre Place, London, United Kingdom, W1F 0DU |
| Telephone | +44 (0)208 142 5409 |
| Website | http://genflowbio.com/ |
| Director | Position |
|---|---|
| Dr Eric Leire | CEO |
| Dr Yassine Bendiabdallah | Non-Executive Chairman |
| Ms Tamara Joseph | Independent Non-Executive Director |
| Dr Guy-Charles Fanneau de la Horie | Independent Non-Executive Director |
| Dr Peter King-Lewis | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | n/a | n/a | n/a |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.11 | 0.38 | 0.26 |
| Cash and equivalents | 0.28 | 0.68 | 2.36 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 0.39 | 1.07 | 2.62 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 0.79 | 0.57 | 0.25 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.79 | 0.57 | 0.25 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | -0.4 | 0.5 | 2.37 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.1 | 0.09 | 0.09 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -5.59 | -4 | -2.14 |
| Share premium account | 4.83 | 4.19 | 4.19 |
| Total equity | -0.4 | 0.5 | 2.37 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 0.32 | 0.17 | -1.33 |
| Pre-tax profit | -1.59 | -1.86 | -1.33 |